OncoMatch/Clinical Trials/NCT05735717

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Is NCT05735717 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hematologic malignancy.

Phase 2RecruitingMasonic Cancer Center, University of MinnesotaNCT05735717Data as of May 2026

Treatment: Fludarabine · Busulfan · Melphalan · Rituximab · Levetiracetam · Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells · Thymoglobulin · Cyclophosphamide — This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Disease stage

Excluded: Stage CML BLAST CRISIS

CML blast crisis [excluded]

Prior therapy

Cannot have received: autologous or allogeneic transplant

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify